# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 12b-25

SEC File Number: 001-37798
NOTIFICATION OF LATE FILING

(Check One):	☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR		
	For Period Ended: June 30, 2023		
	<ul> <li>□ Transition Report on Form 10-K</li> <li>□ Transition Report on Form 20-F</li> <li>□ Transition Report on Form 11-K</li> <li>□ Transition Report on Form 10-Q</li> <li>□ Transition Report on Form N-SAR</li> </ul>		
	For the Transition Period Ended:		

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

# SELECTA BIOSCIENCES, INC.

**Full Name of Registrant** 

Former Name if Applicable

65 Grove Street Address of Principal Executive Office (Street and Number)

> Watertown, Massachusetts 02472 City, State and Zip Code

#### PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### PART III — NARRATIVE

State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The compilation, dissemination and review of the information required to be presented in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 could not be completed and filed by August 14, 2023, without undue hardship and expense to the registrant. The registrant anticipates that it will file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 within the applicable "grace" period provided by Securities Exchange Act Rule 12b-25.

X

### PART IV — OTHER INFORMATION

Carsten Brunn, Ph.D.			
(Name)	617 (Area Code)	923-1400 (Telephone Number)	
Have all other periodic reports required under Section 1. Company Act of 1940 during the preceding 12 months of	3 or 15(d) of the Secu or for such shorter pe	curities Exchange Act of 1934 or Section 30 of the Investment	
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? $\square$ Yes $\boxtimes$ No			
If so: attach an explanation of the anticipated change, be reasonable estimate of the results cannot be made.	oth narratively and qu	uantitatively, and, if appropriate, state the reasons why a	
	,		
sed this notification to be signed on its behalf by the unde	rsigned thereunto dul	aly authorized.	
August 14, 2023	Ву:	/s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer	
	Company Act of 1940 during the preceding 12 months of filed? If the answer is no, identify report(s).   Yes  Is it anticipated that any significant change in results of the earnings statements to be included in the subject rep  If so: attach an explanation of the anticipated change, be reasonable estimate of the results cannot be made.	the earnings statements to be included in the subject report or portion thereo  If so: attach an explanation of the anticipated change, both narratively and q reasonable estimate of the results cannot be made.  Selecta Biosciences, I (Name of Registrant as Specified used this notification to be signed on its behalf by the undersigned thereunto du	